Dow Jones Newswires: Eisai shares rise as FDA memo raises hopes for full approval of Alzheimer’s drug

Eisai shares rose sharply Thursday morning after the U.S. Food and Drug Administration’s review memo on Leqembi raised expectations for full approval of the Alzheimer’s drug.

Previous post : New York to distribute 1 million free N95 masks Thursday amid hazardous smoke levels
Next post It’s now cheaper for travelers to go to Bhutan — if they stay long enough